银屑病
医学
皮肤病科
湿疹性皮炎
不利影响
接触性皮炎
免疫学
过敏
药理学
作者
Adel Alsenaid,Vincent Piguet,Perla Lansang,Yvette Miller-Monthrope,Jensen Yeung,Marissa Joseph
标识
DOI:10.1177/12034754231167140
摘要
Biological treatments targeting IL-17 are highly efficacious with rapid onset of action in psoriasis. Cutaneous adverse events are associated with different biological treatments, including paradoxical psoriasis and eczematous reactions. Brodalumab was previously suggested as an alternative treatment option in psoriasis patients who developed dermatitis or paradoxical psoriasis while on a biologic. Here we report three psoriasis patients who developed brodalumab induced eczematous reaction with complete clearance after switching to risankizumab. Early recognition is crucial for appropriate management. We propose switching patients with psoriasis who develop severe eczematous reaction while on a biologic targeting IL-17 to an IL 23 inhibitor due to efficacy in psoriasis and rarely reported eczematous reaction.
科研通智能强力驱动
Strongly Powered by AbleSci AI